AMVUTTRA™ (vutrisiran) may halt the progression of or reverse the polyneuropathy of hATTR amyloidosis with dosing once every 3 months1,2
AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.1 At 9 months in a randomized, open-label study, patients treated with AMVUTTRA were compared with an external placebo group and demonstrated:
- Improvement in neuropathy impairment, as measured by mNIS+71
- Improvement in quality of life, as measured by Norfolk QoL-DN1
- Improvement in gait speed, as measured by 10MWT1
mNIS+7=modified Neuropathy Impairment Score + 7; Norfolk QoL-DN=Norfolk Quality of Life-Diabetic Neuropathy; 10MWT=10-meter walk test.